Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shutdown Winds Down: Short 'Lapse Period' Likely Means Few Disruptions At US FDA

Executive Summary

FDA lost one work day to the shutdown, but staff may require more time to catch up again.

You may also be interested in...



As US FDA Shutdown Continues, What Will Be The Cost Of Not Spending?

Bolus of applications could be filed once government reopens, but employee morale and recruitment efforts could suffer drop-off.

As US FDA Shutdown Continues, What Will Be The Cost Of Not Spending?

Bolus of applications could be filed once government reopens, but employee morale and recruitment efforts could suffer drop-off.

US FDA Enters Shutdown Mode: Reviews Will Continue, But Will Morale?

User fee funding will allow many functions to continue, but only 58% of staff will be retained until funding deal is reached.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel